Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

The PolyNovo (ASX:PNV) share price is down 30% in 3 months

Shares in PolyNovo Limited (ASX: PNV) sunk 5.6% on Friday following a resignation announcement. Here are the details.

Shares in medical device manufacturer PolyNovo Limited (ASX: PNV) sunk 5.6% on Friday following a resignation announcement.

PolyNovo’s shares have struggled in recent months. Since releasing its FY21 results at the end of June, its market valuation has tumbled by over 30%.

Source: Rask Media PNV 1-year share price chart

COO resignation

PolyNovo told the market on Friday that Anthony Kaye has resigned from his position as Chief Operating Officer. Anthony will be returning to his former workplace, CSL Limited (ASX: CSL) in a more senior position.

During his tenure, Anthony was involved with the completion of PolyNovo’s new manufacturing facility that will make its hernia product and will increase the production of its BTM product.

On the resignation, Managing Director Paul Brennan said “Anthony joined PolyNovo at a critical time to help complete our new manufacturing facility, oversee the commissioning of new machinery and put in place a team to deliver best practice production processes and costs.”

Recent financial results

Covid didn’t make things easy for PolyNovo during FY21.

In the US (its largest market), low vaccination rates have led to lower hospital capacity which negatively impacts the amount of BTM required. This is likely to be transitory however as vaccination rates improve.

On a global scale, hospitals have been unable to accurately forecast their revenues due to COVID. This has meant that getting the BTM product into hospitals has also been a challenge that’s resulted in holding higher levels of inventory.

Revenue from BTM sold in the US was $15.5 million, a 49% increase on FY20.

Excluding some non-cash expenses, PolyNovo made a small net profit after tax of $259k during FY21. However, it looks like it generated a free cash outflow of around $3.8 million.

Summary

There seems to be a lot of things on the horizon for PolyNovo. It plans to grow its share in existing markets, expand into new geographies and develop new products.

The ultimate question, however, is how long will it take to successfully execute its strategy? Notwithstanding Covid, introducing new technology into hospitals can be exceptionally slow for various reasons.

It’s tackling this headwind through the expansion of its sales team, geographic expansion and targeted marketing programs.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content